Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.


All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Novel Prostate Cancer Therapeutic

Inventors at the University of Missouri have demonstrated the proof of concept for combinational therapy of prostate cancer using bacteriotherapy in conjunction with hormone therapy, immunotherapy, or chemotherapy.

Background
Prostate cancer (PC) has a high mortality rate and is one of the most commonly occurring cancers globally. Although chemotherapy and hormone therapy (androgen deprivation therapy, ADT) are commonly used frontline treatments for this disease, they suffer from broad off-target effects and lack of durable efficacy, especially against neuroendocrine prostate cancer (NEPC), a deadly PC subtype. In fact, ADT causes the emergence of therapy resistant NEPC. The median survival benefit for patients treated with chemotherapy and ADT is less than 5 months.

Taking these factors into consideration researchers at the University of Missouri have developed a novel therapy combining an engineered tumor-targeting bacterial strain with a number of chemotherapeutic and immunotherapeutic agents. These novel therapies have been demonstrated successful in animal models, have been shown to target NEPC, and have the potential to revolutionize prostate cancer therapy.

Applications
- Prostate cancer therapy
- Potential for application in additional types of cancer
- Prostate cancer targeted therapeutic load delivery vehicle

Advantages
- Cost effective
- Target NEPC
State of Development
Efficacy has been demonstrated in mouse models of prostate cancer

Additional Details

Owner

University of Missouri-Columbia

Intellectual Property Protection

Patent Issued



Interested? Request More Information